CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Pre-Market Trading 11-21 07:51:44 EST

2.29

-0.11

-4.58%

盘前2.24

-0.05-2.18%

07:45 EST

High2.47	Low2.16	Vol1.27M
Open2.38	D1 Closing2.40	Amplitude12.92%
Mkt Cap40.11M	Tradable Cap31.52M	Total Shares17.52M
T/O2.88M	T/O Rate9.25%	Tradable Shares13.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":2.29,"timestamp":1732136400000,"preClose":2.4,"halted":0,"volume":1273240,"hourTrading":{"tag":"盘前","latestPrice":2.24,"preClose":2.29,"latestTime":"07:45 EST","volume":224,"amount":501.76000000000005,"timestamp":1732193139144},"delay":0,"floatShares":13764800,"shares":17515900,"eps":-7.172755,"marketStatus":"Pre-Market Trading","change":-0.11,"latestTime":"11-21 07:51:44 EST","open":2.38,"high":2.47,"low":2.16,"amount":2881620.4502640003,"amplitude":0.129167,"askPrice":2.45,"askSize":100,"bidPrice":2.03,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-7.172755,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732199400000},"marketStatusCode":1,"adr":0,"exchange":"AMEX","adjPreClose":2.29,"preHourTrading":{"tag":"盘前","latestPrice":2.24,"preClose":2.29,"latestTime":"07:45 EST","volume":224,"amount":501.76000000000005,"timestamp":1732193139144},"postHourTrading":{"tag":"盘后","latestPrice":2.28,"preClose":2.29,"latestTime":"19:51 EST","volume":21086,"amount":47301.2141,"timestamp":1732150260029},"volumeRatio":0.1583832245548531},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2483529536","title":"BRIEF-Calidi Biotherapeutics Announces Closing Of $7.5 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483529536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483529536?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:55","pubTimestamp":1731707758,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Closing Of $7.5 Million Public Offering Of Common StockNov 15 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES CLOSING OF $7.5 MILL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA3VQQ7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483533860","title":"Calidi Biotherapeutics Closes $7.5 Million Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2483533860","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483533860?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:16","pubTimestamp":1731705366,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (CLDI) said Friday it closed its public offering of about 4.4 million common shares at $1.69 per share for gross proceeds of around $7.5 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483253898","title":"Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483253898","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483253898?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:05","pubTimestamp":1731704700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA3VQQ7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483336025","title":"Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483336025","media":"GlobeNewswire","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483336025?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:05","pubTimestamp":1731704700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 15, 2024  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million.Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering.This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-announces-closing-7-210500461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2483368793","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2483368793","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483368793?lang=en_us&edition=fundamental","pubTime":"2024-11-15 03:37","pubTimestamp":1731613073,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics  said Thursday it has priced its offering of about 4.44 million shares at $1.69 apiece, targeting gross proceeds of $7.5 million.The company intends to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.Shares slumped 36% intraday.Bragg Gaming  reported higher Q3 revenue and concluded a strategic review, saying that ongoing execution of its strategy best option to maximize shareholder value. The company also said it is \"currently tracking to the lower end of guidance\" for 2024.Shares sank 27% as intraday trading volume jumped to over 461,000 versus a daily average of about 32,000.Chardan downgraded Allurion Technologies  to neutral from buy following Q3 results released Wednesday.Shares of Allurion sank 25% as intraday trading volume climbed to more than 684,000 from a daily average of roughly 186,000.Price: 2.18, Change: -1.20, Percent Change: -35.50","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4192","BK4150","BK4139","BRAG","ALUR","CLDI"],"gpt_icon":0},{"id":"2483809120","title":"Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809120","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809120?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:25","pubTimestamp":1731594302,"startTime":"0","endTime":"0","summary":"US stocks were treading water ahead of the opening bell Thursday as investors parse initial jobless claims figures and the latest producer price index reading.Dow Jones Industrial Average futures were","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4085","BK4122","BK4595","BK4591","BK4204","BTCS","BK4211","CLDI","XBTmain","GXAI.AU","BK4139","FUNC","BK4557","QUBT","BWMN","BTCmain","BTC.USD.HKCC","GXAI","BK4539","BK4129","BK4094","BK4023","DBGI","NVCT","BK4007","BTCT","HROW"],"gpt_icon":1},{"id":"2483156808","title":"Calidi Biotherapeutics Inc - Prices Public Offering at $1.69 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2483156808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483156808?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:30","pubTimestamp":1731591000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUABSG5YQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2483877431","title":"Investors Await Key Economic Data as US Futures Move Slightly Higher in Thursday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877431","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877431?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:03","pubTimestamp":1731589406,"startTime":"0","endTime":"0","summary":"US stock futures were moving slightly higher in Thursday's premarket session as investors await a raft of economic data set to be released this morning, including initial jobless claims, the producer ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GXAI.AU","BK4122","BTC.USD.HKCC","BK4085","CLDI","GXAI","BK4539","DBGI","BK4211","BWMN","ISBC","BK4129","BK4139","BK4023","BTCT","BK4094","BK4204"],"gpt_icon":1},{"id":"2483647848","title":"Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News","url":"https://stock-news.laohu8.com/highlight/detail?id=2483647848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483647848?lang=en_us&edition=fundamental","pubTime":"2024-11-14 07:58","pubTimestamp":1731542280,"startTime":"0","endTime":"0","summary":"Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering.The stock gained 60% to $3.38 in the regular session Wednesday after its Tuesday earnings report. In after-hours trading, shares were recently down 24% to $2.58.On Tuesday, Calidi reported a wider net loss and said it \"continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies.\" Loss per share narrowed, reflecting a higher number of shares outstanding.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2483865815","title":"Calidi announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865815?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:35","pubTimestamp":1731533728,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics announced that it intends to offer to sell shares of its common stock in an public offering. All of the shares of com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-announces-common-stock-offering-no-amount-given?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-announces-common-stock-offering-no-amount-given?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483863405","title":"Calidi Biotherapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863405?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:33","pubTimestamp":1731533585,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3HVZD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2483632448","title":"Press Release: Calidi Biotherapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2483632448","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483632448?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:33","pubTimestamp":1731533580,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 13, 2024  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock  in an public offering. All of the shares of common stock  are to be sold by the Company.Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offerings.The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.Calidi Biotherapeutics  is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483069597","title":"Calidi Biotherapeutics Q3 2024 GAAP EPS $(0.65) Beats $(0.85) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483069597","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483069597?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:36","pubTimestamp":1731450972,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 53.9 percent increase over losses of $(1.41) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41924324/calidi-biotherapeutics-q3-2024-gaap-eps-0-65-beats-0-85-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Calidi Biotherapeutics Q3 2024 GAAP EPS $(0.65) Beats $(0.85) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI"],"gpt_icon":0},{"id":"2483066496","title":"Calidi Biotherapeutics Inc Qtrly Loss $0.65 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066496?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:29","pubTimestamp":1731450543,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA5C16TH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2483066495","title":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066495?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:29","pubTimestamp":1731450543,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA5C16TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2483066765","title":"Press Release: Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066765?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:29","pubTimestamp":1731450540,"startTime":"0","endTime":"0","summary":"-- Announced FDA Clearance of the Northwestern University IND Application. -- Presented data supporting RTNova , the company's systemic. Virotherapy Conference  in Rotterdam, Netherlands, the Society for. Immunotherapy of Cancer  Annual Meeting, and at Immuno US 2024 in. -- Raised $2 million in a registered direct offering and concurrent private. SAN DIEGO, Nov. 12, 2024  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent business highlights.\"Calidi continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies,\" said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. \"In addition, we are pleased that Northwestern University has received U.S. FDA clearance to advance our CLD-101 program in the clini","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI"],"gpt_icon":0},{"id":"2478933120","title":"Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2478933120","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478933120?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:00","pubTimestamp":1729861200,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc.  and Calidi Biotherapeutics, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-calidi-biotherapeutics-interviews-130000229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","BK4100","BK4099","BK4555","ET","BK4588","NXLIW","NXL","BK4187","BK4139","BK4581","AIRI","BK4561","CLDI","TM","03160","TV","BK4144","BK4585"],"gpt_icon":0},{"id":"2477381236","title":"Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2477381236","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477381236?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:30","pubTimestamp":1729773000,"startTime":"0","endTime":"0","summary":"- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy. - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, offering a potential transformative solution with wide-ranging applications. SAN DIEGO, Oct. 24, 2024  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies and viral vectors, will present data supporting RTNova , the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference  in Rotterdam, Netherlands, October 27-30, 2024, and at Immuno US 2024 in San Diego, October 28-30, 2024. In addition, a poster will be presented at the Society for Immunotherapy of Cancer  Annual Meeting in Houston, November 6-10, 2024.Leading the presentations will be Antonio F. Santidrian, Ph.D., Calidi’s Chief Scientific Officer, and Duong H. Nguyen, Ph.D., Calidi’s Senior Director of Tr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-present-data-supporting-123000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4080","CLDI","SITC","BK4139"],"gpt_icon":0},{"id":"2477568110","title":"Calidi Biotherapeutics Shares Plunge After Pricing $2 Million Direct Offering, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477568110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477568110?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:53","pubTimestamp":1729709584,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (CLDI) shares were down 22% in recent trading on Wednesday after the company said it priced a registered direct offering and concurrent private placement.The biotechnology compa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2477353170","title":"Calidi Biotherapeutics stock tumbles on $2M securities offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2477353170","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477353170?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:30","pubTimestamp":1729690235,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics  shares fell over 10% Wednesday morning after the company priced an offering of 2.05M common shares at $1.00 per share. The clinical-stage biotechnology company also entered into a concurrent private placement to issue series E warrants to purchase up to 2.05M common shares and series F warrants to purchase up to 2.05M common shares. The series E warrants have an exercise price of $1.13 per share, while the series F warrants are exercisable at $1.13 per share. The gross proceeds from the offerings are expected to be approximately $2M. Calidi  intends to use the net proceeds for working capital, general corporate purposes and pre-clinical and clinical trials. Shares of the biotech firm were down more than 10% in premarket trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4194797-calidi-biotherapeutics-tumbles-on-2m-direct-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","CLDI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.3225},{"period":"1month","weight":1.0265},{"period":"3month","weight":0.5903},{"period":"6month","weight":0.0009},{"period":"1year","weight":-0.8653},{"period":"ytd","weight":-0.8483}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.153431},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.08358},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.016188},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.217615},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.004339},{"month":6,"riseRate":1,"avgChangeRate":0.021452},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.069725},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.132691},{"month":9,"riseRate":0,"avgChangeRate":-0.2176},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.099733},{"month":11,"riseRate":0.666667,"avgChangeRate":0.306068},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.091347}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction